MARKET WIREGuruFocus • 22h ago
BGMS Stockholders Plan Sale of 1.1 Million Shares; Company Not PGuruFocus report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
Why BGMS Stock Traded Steady Today — RQD Quant Desk Flash
$0.90 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.90
Bio Green Med Solution Inc. (BGMS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $6.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BGMS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BGMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Bio Green Med Solution Inc. (NASDAQ: BGMS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.90 (0.00% 1D, market cap $6.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BGMS ranks #521 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BGMS compare to ALZN and APRE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BGMS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, BGMS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BGMS?
▼
Per BGMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130166), Bio Green Med Solution Inc. generated $23.6M in revenue (+54773.5% YoY), -$3.0M in net income, and -$4.8M in free cash flow against $8.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.90 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BGMS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY BGMS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)
FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 49.6 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.92+2.2% Next Q
46
Q2 (-2Q)Grade D$0.94+0% Next Q
43
Q3 (-1Q)Grade D$0.94-4.3% Next Q
41
CurrentGrade D-$0.90-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BGMS Turnaround Squeeze
While BGMS currently carries a cautious 38/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.90) and Max Pain ($0.95) forces dealer call-delta covering toward $2.94.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BGMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BGMS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BGMS Stock Traded Steady Today — RQD Quant Desk Flash
Bio Green Med Solution Inc. (BGMS) slipped 0.00% to $0.90, trading at 15% of its 52-week range ($0.57 – $2.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($0.57 – $2.8) with RSI-14 at 49.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BGMS Headlines & Catalysts
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Bio Green Med Solution stock faces dilution from Future NRG dealad-hoc-news.de report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
High Dividend Yield Stocks for IncomeTradingKey report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
BGMS Q3 2024 Earnings: Narrower-Than-Expected Loss per Share, but Stock Slips - SaaS Earnings Trendshttps://www.dars.gov.et/ report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
V-Guard Industries (VGUARD.NS) Eases 0.80% to ₹285.30, Holding Near Midpoint of Trading Band - MA Cross Alerthttps://www.siam.in/ report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 14d ago
12 Health Care Stocks Moving In Monday's After-Market SessionGainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BGMS)
- ✓Walkthrough of BGMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BGMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.62%📐 HORIZONTAL RANGE
2026-11-03O $0.83H $0.90L $0.83C $0.90VOL 11.5K
RES: $1.17SUP: $0.57SMA50: $0.90SMA200: $0.96
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BGMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +54773.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on BGMS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BGMS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BGMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BGMS)
Health Care Rank #521 of 1015
⚔️ ALZN vs BGMS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BGMS vs. ALZN, APRE, ACXP, SKYE)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Bio Green Med Solution Inc. (BGMS) ranks #521 by composite RQD confidence (38/100, grade D-) and #926 by equity capitalization ($6.0M). Within this direct 5-issuer industry benchmark cohort, BGMS leads on earnings valuation at N/A trailing P/E, while BGMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BGMS at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BGMS
ACTIVE
Bio Green Med Solution Inc. | D- | 38/100 | — | — | -35.0% | 0.00% | $6.0M | Benchmark Subject |
| ALZN Alzamend Neuro Inc. | E | 34/100 | — | — | -35.0% | +3.31% | $5.8M | /alzn-vs-bgms → |
| APRE Aprea Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +1.32% | $6.1M | /apre-vs-bgms → |
| ACXP Acurx Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | +2.89% | $5.8M | /acxp-vs-bgms → |
| SKYE Skye Bioscience Inc. | E | 34/100 | — | — | -35.0% | +3.13% | $5.7M | /skye-vs-bgms → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001130166 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bio Green Med Solution Inc. (BGMS) reported GAAP revenue of $23.6M (+54773.5% vs. FY2024 revenue of $43.0K , and -66.9% cumulative change since FY2023) , GAAP net income of -$3.0M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (+40.3% YoY). On the balance sheet, BGMS closed FY2025 with $8.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $23.6M | -$3.0M | -$4.8M | -$4.8M | $8.2M | — |
| FY2024 (FY) | 2024-12-31 | $43.0K | -$11.2M | -$8.0M | -$8.0M | $4.1M | — |
| FY2023 (FY) | 2023-12-31 | $71.3M | $22.6M | -$16.1M | -$16.1M | — | — |
3. BGMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BGMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Bio Green Med Solution Inc. (NASDAQ: BGMS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.90 (0.00% 1D, market cap $6.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BGMS ranks #521 in composite RQD confidence.
How does BGMS compare to ALZN and APRE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BGMS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, BGMS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BGMS?
Per BGMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130166), Bio Green Med Solution Inc. generated $23.6M in revenue (+54773.5% YoY), -$3.0M in net income, and -$4.8M in free cash flow against $8.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BGMS trading relative to its 50-day, 200-day, and 52-week technical levels?
BGMS last traded at $0.90 (0.00% on volume of 10,568 shares), positioning the stock 0.00% above its 50-day simple moving average ($0.90) and -6.25% below its 200-day simple moving average ($0.96). Across its 52-week range of $0.57 to $2.80, BGMS sits at the 14.8% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).
ROARABLE RATING BRIEF • RQD 38/100 (D-)
✓ SEC XBRL & RQD VERIFIED
BGMS — Bio Green Med Solution Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Bio Green Med Solution Inc. (BGMS) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.90 (0.00% 1D, market capitalization $6.0M).
- Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Bio Green Med Solution Inc. Is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Reported revenue is — in each listed fiscal year (), so the company's current income-generating activity cannot be characterized from the provided material.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bio Green Med Solution Inc. (BGMS) reported $23.6M in annual revenue (up from $43.0K in FY2024, +54773.5% YoY) and -$3.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($71.3M revenue, $22.6M net income) through FY2025, BGMS scaled operating cash flow to -$4.8M and free cash flow to -$4.8M, backed by $8.2M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.57 – $2.80 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BGMS carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can BGMS sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $23.6M and free cash flow of -$4.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is BGMS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
BGMS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Bio Green Med Solution Inc. (BGMS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE GuruFocus • 22h ago
BGMS Stockholders Plan Sale of 1.1 Million Shares; Company Not P GuruFocus report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Thursday's After-Market Session Benzinga report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Bio Green Med Solution stock faces dilution from Future NRG deal ad-hoc-news.de report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
High Dividend Yield Stocks for Income TradingKey report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
BGMS Q3 2024 Earnings: Narrower-Than-Expected Loss per Share, but Stock Slips - SaaS Earnings Trends https://www.dars.gov.et/ report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
V-Guard Industries (VGUARD.NS) Eases 0.80% to ₹285.30, Holding Near Midpoint of Trading Band - MA Cross Alert https://www.siam.in/ report covering Bio Green Med Solution Inc. (BGMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 14d ago
12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BGMS Bull vs. Bear Conversation Board — What's Your Call at $0.90?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BGMS 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $1.15 (+27.8%)
📌 Pinned Debate The stock trades at $0.83 with a market cap of $5.5M and a Roarable RQD score that is still assigned a 10/20 macro fit pillar on a beta
Picked up a starter position in BGMS in my $100K Virtual Cash book at $0.90. The stock trades at $0.83 with a market cap of $5.5M and a Roarable RQD score that is still assigned a 10/20 macro fit pillar on a beta of 1.0.. Trading inside a $0.57–$2.80 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
ArenaChamp_24 🐂 BULL
@DeltaGamma_99 Agree on the RQD 38/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.90 and keeping dry powder in case we test $0.84.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $0.75 (-16.7%)
Spot @ $0.90 Reported revenue is $0.0M in every period, ROIC is -35%, and FCF is negative in each year, with a Piotroski F-Score of 2/9.
Fading this rally in BGMS at $0.90. Reported revenue is $0.0M in every period, ROIC is -35%, and FCF is negative in each year, with a Piotroski F-Score of 2/9.. With a beta of 1.0 and the stock sitting at $0.90 (52-wk range $0.57–$2.80), the easy multiple expansion is already priced in.